| 1 |
NCT03641950 |
Completed |
The Objective of This Study is to Evaluate the Efficacy and Safety of Botulax® in Patients With Essential Blepharospasm. |
|
- Drug: Botulinum toxin type A
|
Interventional
|
Phase 4 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Total score change from baseline at 4 weeks post-injection of Jankovic Rating scale
- Total score change from baseline at 16 weeks post-injection of Jankovic Rating scale
- Change from baseline at 4 weeks and 16 weeks of Disability Index
- (and 2 more...)
|
249 |
All |
18 Years and older (Adult, Older Adult) |
NCT03641950 |
HG-BOT-IV3 |
|
April 30, 2015 |
May 2015 |
January 7, 2016 |
August 22, 2018 |
August 22, 2018 |
|
- Hugel
Seoul, Korea, Korea, Republic of
|
|
| 2 |
NCT02765113 |
Unknown † |
Two Different Surgical Methods of Blepharospasm |
|
- Procedure: Facial nerve combing
- Procedure: Facial and Trigeminal nerve combing
|
Interventional
|
Early Phase 1 |
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Improvement of symptoms in patients with blepharospasm
- Incidence of facial numbness
- Incidence of facial paralysis
|
40 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT02765113 |
XH-16-008 |
|
May 2016 |
December 2017 |
December 2017 |
May 6, 2016 |
May 6, 2016 |
|
|
|
| 3 |
NCT03269123 |
Completed |
A Mechanical Device for Blepharospasm |
|
|
Interventional
|
Not Applicable |
- Oxford University Hospitals NHS Trust
- The Dystonia Society of the United Kingdom
- Globsource UK
- Statsconsultancy Ltd, Amersham, Buckinghamshire,UK
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The study's objective and subjective responses for the use of the device is measured with the CDQ-24 questionnaire and a questionnaire specific to the the device
- The proportion of patients demonstrating the "Geste Antagoniste" phenomenon.
|
58 |
All |
18 Years and older (Adult, Older Adult) |
NCT03269123 |
5663 |
|
March 2, 2010 |
August 8, 2011 |
August 8, 2011 |
August 31, 2017 |
August 31, 2017 |
|
|
|
| 4 |
NCT02780336 |
Recruiting |
Blepharospasm Tools |
- Blepharospasm
- Dystonia
- Other Eye and Face Disorders
|
|
Observational
|
|
- Emory University
- Benign Essential Blepharospasm Research Foundation
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Blepharospasm Diagnostic Rating Scale (BDRS)
- Blepharospasm Severity Rating Scale (BSRS)
- Blepharospasm Screening Questions - Motor (BSQ-M)
- (and 14 more...)
|
400 |
All |
18 Years and older (Adult, Older Adult) |
NCT02780336 |
IRB00087047
U54TR001456 |
|
August 2016 |
February 2019 |
February 2019 |
May 23, 2016 |
August 8, 2018 |
|
- University of Colorado Denver
Aurora, Colorado, United States - Emory University
Atlanta, Georgia, United States - Rush University
Chicago, Illinois, United States - (and 8 more...)
|
|
| 5 |
NCT01686061 |
Completed |
Blepharospasm Patient Survey for Patients With Blepharospasm |
|
- Other: No intervention- only one time survey
|
Observational
|
|
|
Industry |
|
- Botulinum Toxin Treatment Information
|
124 |
All |
18 Years to 81 Years (Adult, Older Adult) |
NCT01686061 |
MUS6020100920 |
|
September 2012 |
April 2013 |
April 2013 |
September 17, 2012 |
April 8, 2014 |
|
- Merz Investigative Site #0007
Fountain Valley, California, United States - Merz Investigative Site # 0002
Sarasota, Florida, United States - Merz Investigative Site # 0001
Boston, Massachusetts, United States - (and 2 more...)
|
|
| 6 |
NCT03263000 |
Recruiting |
Photic Blink Reflex in People With Blepharospasm and Increased Blinking |
|
|
Observational
|
|
- National Institute of Neurological Disorders and Stroke (NINDS)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Case-Control
- Time Perspective: Cross-Sectional
|
- Photic blink reflex recovery cycle
- Electrocutaneous blink reflex recovery cycle; Blink rate; Light Questionnaire Scale
|
72 |
All |
18 Years and older (Adult, Older Adult) |
NCT03263000 |
170159
17-N-0159 |
|
October 30, 2017 |
December 31, 2019 |
December 31, 2019 |
August 28, 2017 |
June 27, 2018 |
|
- National Institutes of Health Clinical Center
Bethesda, Maryland, United States
|
|
| 7 |
NCT02327728 |
Unknown † |
Comparison of Different Botulinum Toxin A Injection Patterns in the Treatment of Blepharospasm |
|
- Procedure: Botulinum toxin A injection (5 sites: 12.5U)
- Procedure: Botulinum toxin A injection (4 sites: 10U)
- Drug: Botulinum toxin A 12.5U
- Drug: Botulinum toxin A 10U
|
Interventional
|
Not Applicable |
- YangHui
- Sun Yat-sen University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Changes of Jankovic rating scale (JRS) from baseline at 1week, 1month and 3 months
- Changes of lower lid tear meniscus height (TMH) from baseline at 1week, 1month and 3 months
- Changes of blepharospasm disability index (BSDI) from baseline at 1week, 1month and 3 months
- (and 4 more...)
|
120 |
All |
18 Years and older (Adult, Older Adult) |
NCT02327728 |
ZOC00173 |
|
February 2013 |
December 2015 |
December 2015 |
December 30, 2014 |
December 30, 2014 |
|
- Zhongshan Ophthalmic Center, SunYat-senU
Guangzhou, Guangdong, China
|
|
| 8 |
NCT01287247 |
Completed |
Trial Evaluating Xeomin® (incobotulinumtoxinA) for Cervical Dystonia or Blepharospasm in the United States |
- Cervical Dystonia
- Blepharospasm
|
|
Observational
|
|
- Merz North America, Inc.
- Registrat-Mapi
|
Industry / Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Determination of injection patterns and techniques
- To collect and evaluate efficacy of Xeomin®(incobotulinumtoxinA) including onset and offset of effect as well as improvement of disease specific and global illness severity
|
688 |
All |
18 Years and older (Adult, Older Adult) |
NCT01287247 |
MRZ 60201-4066-5 |
XCiDaBLE |
February 2011 |
April 2013 |
April 2013 |
February 1, 2011 |
April 10, 2015 |
|
- Site #001052
Cullman, Alabama, United States - Scottsdale, Arizona, United States
- Site # 001974
Tucson, Arizona, United States - (and 67 more...)
|
|
| 9 |
NCT01750346 |
Terminated
Has Results |
Acetyl Hexapeptide-8 for Blepharospasm |
|
- Drug: Topical acetyl hexapeptide-8
- Drug: Placebo
|
Interventional
|
Phase 2 |
- National Institute of Neurological Disorders and Stroke (NINDS)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- The Jankovic Blepharospasm Rating Scale at 2 Month
- The Jankovic Blepharospasm Rating Scale at 1 Month
- The Blepharospasm Disability Scale at 1 Month
- (and 4 more...)
|
8 |
All |
18 Years and older (Adult, Older Adult) |
NCT01750346 |
130022
13-N-0022 |
|
November 2012 |
May 2015 |
May 2015 |
December 17, 2012 |
November 10, 2016 |
November 10, 2016 |
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
|
| 10 |
NCT00942851 |
Completed
Has Results |
A Study of Acetyl Hexapeptide-8 (AH8) in Treatment of Blepharospasm |
|
- Drug: Acetyl-Hexapeptide Topical Treatment
- Drug: placebo
|
Interventional
|
Phase 1
Phase 2 |
- National Institute of Neurological Disorders and Stroke (NINDS)
- BCN Peptides
- National Institutes of Health Clinical Center (CC)
|
NIH / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Time Until Jankovic Blepharospasm Rating Scale (JBRS) Reverts Back to Baseline
- Change in the JBRS at 3 Months
- % Blepharospasm Disability Scale (BDS) Change at 3 Months
|
24 |
All |
18 Years and older (Adult, Older Adult) |
NCT00942851 |
090193
09-N-0193 |
|
July 2009 |
October 2010 |
October 2010 |
July 21, 2009 |
September 6, 2012 |
September 6, 2012 |
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
|
| 11 |
NCT02947815 |
Unknown † |
Safety and Efficacy of NABOTA in Treatment of Essential Blepharospasm |
|
- Drug: Clostridium Botulinum Toxin Type A
|
Interventional
|
Phase 2
Phase 3 |
- Daewoong Pharmaceutical Co. LTD.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- The change from baseline in Scott's Scale Score
|
234 |
All |
18 Years and older (Adult, Older Adult) |
NCT02947815 |
DW_DWP450007 |
|
October 2016 |
October 2017 |
December 2017 |
October 28, 2016 |
October 28, 2016 |
|
- the catholic university of korea, Seoul ST. Mary's Hospital.
Seoul, Korea, Republic of
|
|
| 12 |
NCT00682760 |
Completed |
Comparison of Korean Botulinum Toxin Type A Versus Botox in the Treatment of Essential Blepharospasm |
|
- Drug: Korean Botulinum toxin type A (KbtxA) and Botox injection
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- The improvement of severity of spasm at 4 weeks post-injection as a primary efficacy outcome, qualifying non inferiority to the control group
- Changes in eyelid closure force and functional visual status after injection for secondary efficacy outcomes
|
60 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT00682760 |
Meditoxin_Botox
Meditoxin-05-01 |
|
October 2005 |
February 2006 |
August 2006 |
May 22, 2008 |
May 22, 2008 |
|
- Sang Yeul Lee
Seoul, Korea, Republic of
|
|
| 13 |
NCT00761592 |
Completed
Has Results |
Comparison of Two Botulinum Type A Products in the Treatment of Blepharospasm |
|
- Biological: Botulinum Toxin Type A 900kDa
- Biological: Botulinum Toxin Type A 150kDa
|
Interventional
|
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change From Baseline to Week 4 in Blepharospasm Disability Index
- Change From Baseline to Week 8 in Blepharospasm Disability Index
- Change From Baseline to Week 4 and Week 8 in Total Jankovic Rating Scale (JRS) (Severity and Frequency Measured on a Scale of 0-4)
- (and 2 more...)
|
65 |
All |
18 Years and older (Adult, Older Adult) |
NCT00761592 |
ALLBL001 |
|
July 2006 |
January 2008 |
January 2008 |
September 29, 2008 |
November 19, 2013 |
July 9, 2009 |
- Bonn, Germany
- Wiesbaden, Germany
- Zwickau, Germany
|
|
| 14 |
NCT03216473 |
Completed |
Clinical Study to Evaluate the Efficacy and Safety of Neuronox and Botox With Essential Blepharospasm |
|
- Drug: Neuronox
- Drug: Botox
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- JRS (Jankovic Rating Scale) sum-score
|
140 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03216473 |
TG1221MED |
|
May 25, 2016 |
March 17, 2017 |
July 4, 2017 |
July 13, 2017 |
July 13, 2017 |
|
|
|
| 15 |
NCT02370875 |
Completed |
rTMS and Botulinum Toxin in Benign Essential Blepharospasm |
- Benign Essential Blepharospasm
|
- Device: Magstim RapidStim2
- Device: Sham Magstim RapidStim2
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Eye Blink Rate
- Number of sustained blinks
- Time of eye closure
- (and 4 more...)
|
25 |
All |
30 Years to 75 Years (Adult, Older Adult) |
NCT02370875 |
201400993 |
|
February 2015 |
May 2017 |
November 2017 |
February 25, 2015 |
December 13, 2017 |
|
- Center for Movement Disorders and Neurorestoration
Gainesville, Florida, United States
|
|
| 16 |
NCT01259557 |
Completed |
Efficacy and Safety Study of Meditoxin® to Treat Essential Blepharospasm |
|
- Drug: Botulinum Toxin Type A
|
Interventional
|
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- the change rate of Jankovic Rating Scale score
- the change rate of Jankovic Rating Scale scale
- the change rate of Blepharospasm Disability Index
- (and 2 more...)
|
110 |
All |
18 Years and older (Adult, Older Adult) |
NCT01259557 |
MT-PRT-BP02 |
|
August 2010 |
May 2011 |
August 2011 |
December 14, 2010 |
April 25, 2012 |
|
- Sevrance Hospital
Seoul, Korea, Republic of - Seoul St.Mary Hospital
Seoul, Korea, Republic of - Chung-Ang Univesity Yongsan Hospital
Seoul, Korea, Republic of
|
|
| 17 |
NCT00234507 |
Completed |
Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential Blepharospasm |
|
- Drug: Botulinum toxin type A (Dysport®)
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- The functional disability as measured by the percentage of normal activity (PNA) derived from the Blepharospasm Disability Scale (BDS) at 4 weeks post-treatment.
- Frequency of involuntary movements (FIM) and severity of oculo-facial spasm (measured by the Severity Rating Scale [SRS]) at 4 weeks post-treatment.
- PNA, FIM and SRS at 8, 12 and 16 weeks post-treatment.
- (and 6 more...)
|
120 |
All |
18 Years and older (Adult, Older Adult) |
NCT00234507 |
Y-47-52120-706 |
|
January 2003 |
|
May 2004 |
October 7, 2005 |
December 13, 2018 |
|
- Banner Health Research Institute
Phoenix, Arizona, United States - Neurological Institute
Phoenix, Arizona, United States - The Parkinson's and Movement Disorder Institute
Fountain Valley, California, United States - (and 11 more...)
|
|
| 18 |
NCT00500799 |
Completed |
Brain Changes in Blepharospasm |
|
|
Observational
|
|
- National Institute of Neurological Disorders and Stroke (NINDS)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Time Perspective: Prospective
|
|
72 |
All |
18 Years and older (Adult, Older Adult) |
NCT00500799 |
070191
07-N-0191 |
|
July 9, 2007 |
|
April 14, 2009 |
July 13, 2007 |
July 2, 2017 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
|
| 19 |
NCT00406367 |
Completed
Has Results |
IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm |
|
- Drug: incobotulinumtoxinA (Xeomin)
- Drug: Placebo
|
Interventional
|
Phase 3 |
- Merz Pharmaceuticals GmbH
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Jankovic Rating Scale (JRS) Change From Baseline in the JRS Severity Subscore at Week 6 After Injection (Assessed by a Blinded Independent Rater)
- Jankovic Rating Scale (JRS) Change From Baseline in the JRS Severity Subscore at Week 6 After Injection (Assessed by Subject Diary)
- Blepharospasm Disability Index (BSDI) Change From Baseline in the BSDI at Week 6 After Injection
- Patient Evaluation of Global Response (PEGR) at Final Visit
|
109 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT00406367 |
MRZ 60201-0433 |
|
October 2006 |
April 2008 |
July 2009 |
December 4, 2006 |
March 15, 2013 |
November 16, 2010 |
- Baylor College of Medicine
Houston, Texas, United States - David King, MD - Private Practice
Halifax, Nova Scotia, Canada
|
|
| 20 |
NCT00507637 |
Terminated |
Blepharospasm Short Interval |
|
|
Interventional
|
Phase 2 |
- Merz Pharmaceuticals GmbH
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The difference between the actual Blepharospasm Disability Index [BSDI] value at each follow up visit and the BSDI value at baseline.
- Change in Jankovic Rating Scale (JRS) score from baseline over time.
- Patient Evaluation of Global Response [PEGR] rated by patient at visits V2 to V8 and at follow-up visit
|
8 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT00507637 |
MRZ 60201-0703/1
2007-000697-23 |
|
August 2007 |
February 2008 |
February 2008 |
July 26, 2007 |
February 6, 2012 |
|
- Universitaets Augenklinik
Bonn, Germany
|
|
| 21 |
NCT01791881 |
Completed |
Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of "Hugeltox Inj." in Essential Blepharospasm |
|
- Drug: Hugeltox
- Drug: Botulinum Toxin Type A(Botox®)
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Rate of patients with an improvement more than one Grade of Severity of Spasm (by Scott's Method)
- (1) Duration of action days
- (2) Grades of Severity of Spasm (by Scott's Method), Functional Visual Status
- (and 2 more...)
|
172 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT01791881 |
HG-06-01 |
|
April 2008 |
May 2009 |
July 2009 |
February 15, 2013 |
February 15, 2013 |
|
- Cha Hospital
Bundang, Korea, Republic of - Seoul National University Hospital - Bundang
Bundang, Korea, Republic of - Youngnam University Hospital
Daegu, Korea, Republic of - (and 6 more...)
|
|
| 22 |
NCT01896895 |
Completed
Has Results |
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Abnormal Contraction or Twitch of the Eyelid |
- Bilateral Blepharospasm (BEB)
|
- Drug: IncobulinumtoxinA (Xeomin), 25 Units
- Drug: IncobotulinumtoxinA (Xeomin), 12.5 Units
- Drug: Placebo
- Drug: IncobotulinumtoxinA (Xeomin), 35 Units
|
Interventional
|
Phase 3 |
- Merz Pharmaceuticals GmbH
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Double-blind MP: Change From Baseline in JRS Severity Subscore at Day 43 (Visit 4)
- Double-blind MP: Change From Baseline in Blepharospasm Disability Index (BSDI) at Day 43 (Visit 4)
- Double-blind MP: Patient Evaluation of Global Response (PEGR) at Final Visit (Day 43-Day 141)
|
61 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT01896895 |
MRZ60201_3074_1
2012-004821-26 |
|
November 2013 |
April 2016 |
November 2016 |
July 11, 2013 |
March 1, 2018 |
March 1, 2018 |
- Merz Investigational Site #030002
Athens, Greece - Merz Investigational Site #030001
Athens, Greece - Merz Investigational Site #060007
Georgetown, Penang, Malaysia - (and 8 more...)
|
|
| 23 |
NCT01759745 |
Unknown † |
Influence of Gaze Shift and Emotions on Symptoms of Blepharospasm |
|
|
Observational
|
|
- Kirsten Elwischger, MD
- Medical University of Vienna
|
Other |
- Observational Model: Case Control
- Time Perspective: Prospective
|
- Duration and frequency of pupillary occlusion
- Number of blinks and spasms.
|
40 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT01759745 |
BEB_Gaze_Emotion |
|
December 2014 |
December 2015 |
December 2015 |
January 3, 2013 |
July 1, 2014 |
|
- Department of Neurology, Medical University of Vienna
Vienna, Austria
|
|
| 24 |
NCT00411255 |
Completed |
Brain Stimulation to Treat Blepharospasm or Meige Syndrome |
- Blepharospasm
- Focal Dystonia
|
- Procedure: repetitive transcranial magnetic stimulation (rTMS)
|
Interventional
|
Phase 2 |
- National Institute of Neurological Disorders and Stroke (NINDS)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Intervention Model: Crossover Assignment
- Masking: Single (Participant)
- Primary Purpose: Supportive Care
|
- Patient report the subject rating of their symptoms before and after intervention.
|
22 |
All |
18 Years and older (Adult, Older Adult) |
NCT00411255 |
060192
06-N-0192 |
|
June 22, 2006 |
April 7, 2009 |
April 7, 2009 |
December 13, 2006 |
July 2, 2017 |
|
- National Institute of Neurological Disorders and Stroke (NINDS), 9000 Rockville
Bethesda, Maryland, United States
|
|
| 25 |
NCT01814774 |
Completed
Has Results |
A Retrospective Chart Review of BOTOX® and Xeomin® for the Treatment of Cervical Dystonia and Blepharospasm |
- Cervical Dystonia
- Blepharospasm
|
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Dose of Botulinum Toxin Used to Treat Cervical Dystonia
- Dose of Botulinum Toxin Used to Treat Blepharospasm
- Number of Participants With Adverse Events
- Botulinum Toxin Inter-injection Interval
|
48 |
All |
18 Years and older (Adult, Older Adult) |
NCT01814774 |
TRU2011 |
|
January 2013 |
July 2013 |
July 2013 |
March 20, 2013 |
July 3, 2014 |
July 3, 2014 |
- Bergen, Norway
- Wakefield, United Kingdom
|
|
| 26 |
NCT02245958 |
Completed |
A Retrospective Chart Review of BOTOX® and Xeomin® for the Management of Cervical Dystonia and Blepharospasm |
- Cervical Dystonia
- Blepharospasm
|
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Dose of Botulinum Toxin Used to Treat Cervical Dystonia
- Dose of Botulinum Toxin Used to Treat Blepharospasm
- Botulinum Toxin Inter-injection Intervals
- (and 2 more...)
|
44 |
All |
18 Years and older (Adult, Older Adult) |
NCT02245958 |
GMA-US-NEU-0271 |
|
August 2015 |
December 2015 |
December 2015 |
September 22, 2014 |
January 8, 2016 |
|
- Colonia Roma Z.P., Mexico
- Wakefield, United Kingdom
|
|
| 27 |
NCT02577224 |
Unknown † |
An RCT of a Patient-initiated Treatment Service for BEB and HFS |
- Blepharospasm
- Hemi Facial Spasm
|
- Other: Patient-initiated treatment
|
Interventional
|
Not Applicable |
- Moorfields Eye Hospital NHS Foundation Trust
- Merz Pharmaceuticals
- City, University of London
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Health Services Research
|
- Disease severity
- Disability
- Patient satisfaction
- (and 8 more...)
|
130 |
All |
18 Years and older (Adult, Older Adult) |
NCT02577224 |
EZRD1024 |
|
August 2015 |
October 2017 |
October 2017 |
October 16, 2015 |
March 22, 2017 |
|
- Moorfields Eye Hospital NHS Foundation Trust
London, United Kingdom
|
|
| 28 |
NCT03508882 |
Active, not recruiting |
Pretarsal Versus Preseptal Botulinum Toxin for Patients With Eyelid Spasm |
- Blepharospasm
- Hemifacial Spasm
- Botulinum Toxins, Type A
|
- Drug: Botulinum Toxin Type A 100Unit/Vial (Product)
- Drug: Saline Solution for Injection
|
Interventional
|
Phase 4 |
- The University of Hong Kong
- Food and Health Bureau, Hong Kong
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Care Provider, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Jankovic Rating Scale (JRS)
- Toronto (TWSTRS)
- Blepharospasm Disability Index (BSDI)
- (and 4 more...)
|
100 |
All |
18 Years and older (Adult, Older Adult) |
NCT03508882 |
HMRF Project No.: 12133171
Protocol : MMBT; v1.3;1Mar16 |
|
July 1, 2015 |
October 31, 2017 |
April 30, 2018 |
April 26, 2018 |
May 1, 2018 |
|
|
|
| 29 |
NCT00487383 |
Terminated |
Brain Changes in Blepharospasm |
- Dystonia
- Focal Dystonia
- Cerebellar Disease
|
|
Observational
|
|
- National Institute of Neurological Disorders and Stroke (NINDS)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Time Perspective: Prospective
|
|
47 |
All |
18 Years to 85 Years (Adult, Older Adult) |
NCT00487383 |
070165
07-N-0165 |
|
June 12, 2007 |
|
June 29, 2012 |
June 18, 2007 |
February 15, 2019 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
|
| 30 |
NCT01546805 |
Unknown † |
Testing the Effect of Zinc Supplementation to Improve the Treatment Effect of Botulinum Toxin for Oculofacial Spasm |
- Blepharospasm
- Hemifacial Spasm
|
- Drug: Zinc Supplement
- Drug: Sugar pill
|
Interventional
|
Not Applicable |
- St. Joseph's Healthcare Hamilton
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Jankovic Rating Scale
- Treatment Duration Cycle
- Blepharospasm Disability Index (BDI)
|
40 |
All |
18 Years and older (Adult, Older Adult) |
NCT01546805 |
R.P. #11-3601 |
|
April 2012 |
December 2012 |
March 2013 |
March 7, 2012 |
March 7, 2012 |
|
- St Joseph's Hospital Hamilton
Hamilton, Ontario, Canada - Carrot Eye Centre
Mississauga, Ontario, Canada
|
|
| 31 |
NCT01168388 |
Completed |
Movement Disorder Survey in East China |
- Primary Dystonia
- Hemifacial Spasm
|
|
Observational
|
|
- Sir Run Run Shaw Hospital
- GlaxoSmithKline
|
Other / Industry |
- Time Perspective: Prospective
|
- Number of participants with primary dystonia
- Number of participants with hemifacial spasm
- Number of participants with blepharospasm
|
1600 |
All |
Child, Adult, Older Adult |
NCT01168388 |
SirRRSH-001 |
MDS |
April 2010 |
August 2010 |
August 2010 |
July 23, 2010 |
July 21, 2011 |
|
- Sir Run Run Shaw Hospital
Hangzhou, Zhejiang, China
|
|
| 32 |
NCT03399292 |
Recruiting |
Effect of Lipid Based Eye Drops on Tear Film Lipid Layer Thickness |
|
- Drug: Cationorm MD sine eye drops
|
Observational
|
|
- Medical University of Vienna
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Tear film lipid layer thickness as measured with Lipiview II
|
40 |
All |
18 Years and older (Adult, Older Adult) |
NCT03399292 |
OPHT-031116 |
|
April 12, 2017 |
August 2019 |
December 2019 |
January 16, 2018 |
June 8, 2018 |
|
- Department of Clinical Pharmacology, Medical University of Vienna
Vienna, Austria
|
|
| 33 |
NCT00535938 |
Completed
Has Results |
MDs on Botox Utility (MOBILITY) |
- Blepharospasm
- Torticollis
- Strabismus
- Muscle Spasticity
|
- Other: botulinum toxin type A
|
Observational
|
|
|
Industry |
- Time Perspective: Prospective
|
- Change From Baseline in the SF-6D Measure Health Utility (Quality of Life) Score Using the SF-12® Questionnaire for Patients With Cervical Dystonia
- Change From Baseline in the SF-6D Measure Health Utility (Quality of Life) Score Using the SF-12® Questionnaire for Patients With Blepharospasm
- Change From Baseline in the SF-6D Measure Health Utility (Quality of Life) Score Using the SF-12® Questionnaire for Patients With Hyperhidrosis
- (and 13 more...)
|
1372 |
All |
14 Years and older (Child, Adult, Older Adult) |
NCT00535938 |
AGN/MMC B00705 |
|
September 2007 |
September 2013 |
September 2013 |
September 27, 2007 |
September 10, 2014 |
September 10, 2014 |
|
|
| 34 |
NCT00001784 |
Completed |
Mexiletine for the Treatment of Focal Dystonia |
- Blepharospasm
- Dystonia
- Spasm
|
|
Interventional
|
Phase 2 |
- National Institute of Neurological Disorders and Stroke (NINDS)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Primary Purpose: Treatment
|
|
24 |
All |
Child, Adult, Older Adult |
NCT00001784 |
980130
98-N-0130 |
|
July 1998 |
|
July 2002 |
November 4, 1999 |
March 4, 2008 |
|
- National Institute of Neurological Disorders and Stroke (NINDS)
Bethesda, Maryland, United States
|
|
| 35 |
NCT03184597 |
Recruiting |
HLA Screening in Reducing the Risk of Antiepileptic Drug-induced Cutaneous Adverse Reactions |
- Epilepsy
- Neuropathy
- Psychiatric Illness
- Blepharospasm
|
- Diagnostic Test: HLA screening before commencing aromatic AEDs
|
Interventional
|
Not Applicable |
- Second Affiliated Hospital of Guangzhou Medical University
- Guangzhou First People's Hospital
- West China Hospital
- (and 6 more...)
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- AEDs-induced cADRs incidence
|
4000 |
All |
Child, Adult, Older Adult |
NCT03184597 |
2017-hs-30 |
|
August 1, 2017 |
June 2021 |
June 2021 |
June 12, 2017 |
September 5, 2018 |
|
- The Second Affiliated Hospital of Guangzhou Medical Universty
Guangzhou, Guangdong, China
|
|
| 36 |
NCT01373424 |
Recruiting |
The Dystonia Coalition Natural History and Biospecimen Repository for Isolated Dystonias |
|
|
Observational
|
|
- Hyder A. Jinnah, MD, PhD
- National Institute of Neurological Disorders and Stroke (NINDS)
- Office of Rare Diseases (ORD)
- (and 3 more...)
|
Other / NIH / Industry |
- Observational Model: Other
- Time Perspective: Other
|
|
5000 |
All |
18 Years and older (Adult, Older Adult) |
NCT01373424 |
IRB00046266
U54TR001456
RDCRN#6301
U54NS065701 |
DCP |
January 2011 |
June 2020 |
August 2021 |
June 15, 2011 |
August 8, 2018 |
|
- University of Alabama, Birmingham
Birmingham, Alabama, United States - Mayo Clinic, Arizona
Scottsdale, Arizona, United States - Parkinson's and Movement Disorders Institute
Fountain Valley, California, United States - (and 39 more...)
|
|
| 37 |
NCT03373162 |
Completed |
Functional Effects of Botox on the Brain Using MRS and fMRI |
|
|
Interventional
|
Phase 4 |
- University of California, Irvine
- Allergan
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- MRS in brainstem
- functional MRI in amygdala and rest of brain
- Structural brain volume changes
|
10 |
Female |
30 Years to 40 Years (Adult) |
NCT03373162 |
2017-3377 |
|
September 30, 2017 |
November 1, 2017 |
November 1, 2017 |
December 14, 2017 |
February 5, 2018 |
|
- University of California, Irvine
Irvine, California, United States
|
|
| 38 |
NCT02112097 |
Unknown † |
ASIS for Enbrel in Plaque Psoriasis |
|
- Drug: Gadolinium
- Drug: Efficacy of Enbrel subcutaneously at Week 12
- Drug: Efficacy of Enbrel subcutaneously at Week 24
- (and 12 more...)
|
Interventional
|
Phase 1
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Relative Prolongation Ability Score for Gadolinium subdermally injected.
- Efficacy of Enbrel subcutaneously vs. subdermally in Plaque Psoriasis.
|
60 |
All |
21 Years to 65 Years (Adult, Older Adult) |
NCT02112097 |
NCTAR066986
R44AR066986 |
ASISinPP |
January 2016 |
June 2016 |
June 2017 |
April 11, 2014 |
June 24, 2015 |
|
- Automatic Subdermal Injector System, Inc
Westminster, California, United States - Automatic Subdermal Injector System, Inc
Westminster, California, United States
|
|
| 39 |
NCT02555982 |
Unknown † |
Evaluation of Botulinum Toxin Injection Efficacy in the Treatment of Head Essential Tremor |
|
- Drug: BOTOX ® 200 Unités
- Drug: Placebo
|
Interventional
|
Phase 3 |
- University Hospital, Clermont-Ferrand
- Allergan
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- clinical state improvement of patients evaluated by the Clinical Global Impression of Change (CGI)
- % of responders defined with CGI
- The Fahn-Tolosa-Marin Tremor Rating Scale (TRS) (sub item head)
- (and 5 more...)
|
120 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT02555982 |
CHU-0245
2015-000162-59 |
Btx-HT |
June 2016 |
July 2017 |
December 2017 |
September 22, 2015 |
July 26, 2016 |
|
- CHU de Clermont-Ferrand
Clermont-Ferrand, France
|
|
| 40 |
NCT02604186 |
Completed |
Effects of Botulinum Toxin Injections in Patients With Hereditary Spastic Paraplegia |
- Hereditary Spastic Paraplegia
|
- Other: Botulinum Toxin Injections
- Other: Placebo Injections
|
Interventional
|
Phase 2
Phase 3 |
- University of Campinas, Brazil
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Cristália Produtos Químicos Farmacêuticos Ltda.
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from baseline in 10 meter maximum gate velocity
- Change from baseline in Spastic Paraplegia Rating Scale (SPRS),
- Change from baseline in Ashworth spasticity scale of adductors and triceps surae muscles
- (and 5 more...)
|
55 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT02604186 |
CAAE: 48177315.9.1001.5404 |
SPASTOX |
March 9, 2016 |
March 15, 2017 |
March 15, 2017 |
November 13, 2015 |
November 7, 2017 |
|
- Univeristy of Campinas Hospital
Campinas, SP, Brazil
|
|
| 41 |
NCT03186001 |
Not yet recruiting |
Frontalis Botulinum Toxin |
|
- Drug: Abobotulinum toxin A
|
Interventional
|
Phase 4 |
- St Joseph University, Beirut, Lebanon
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Objective assessment
- 1-Investigators Global Aesthetic Improvement Scale
- 2-Patient satisfaction
- (and 3 more...)
|
30 |
Female |
30 Years to 60 Years (Adult) |
NCT03186001 |
USJ-06 |
|
July 1, 2017 |
August 1, 2017 |
August 1, 2017 |
June 14, 2017 |
June 14, 2017 |
|
- Saint Joseph University
Beirut, Lebanon
|
|
| 42 |
NCT01233999 |
Completed
Has Results |
Botulinum Toxin in the Treatment of Raynaud's |
|
|
Interventional
|
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: Triple (Participant, Care Provider, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Mean Digital Temperature Difference From Baseline
|
10 |
All |
18 Years to 89 Years (Adult, Older Adult) |
NCT01233999 |
IRB00015510 |
|
October 2010 |
October 2011 |
March 2012 |
November 4, 2010 |
April 21, 2014 |
April 21, 2014 |
- Emory University
Atlanta, Georgia, United States
|
|
| 43 |
NCT02179450 |
Completed |
Cognitive Function and Emotional Possessing in Bilateral Facial Palsy |
|
|
Observational
|
|
- Kirsten Elwischger, MD
- Medical University of Vienna
|
Other |
- Observational Model: Case Control
- Time Perspective: Prospective
|
- I-S-T-2000R- (intelligence-structure-test 2000R)
- Beck's depression-inventory-II
- Apathy Evaluation Scale
|
84 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT02179450 |
Cognition_Facial palsy |
|
August 2012 |
May 2013 |
December 2013 |
July 1, 2014 |
July 1, 2014 |
|
- Department of Neurology, Medical University of Vienna
Vienna, Austria
|
|
| 44 |
NCT00753831 |
Completed |
Efficacy of Aurosling in Frontalis Sling Suspension Surgery |
|
|
Interventional
|
Phase 4 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Ptosis Correction
- Adverse Events
|
16 |
All |
Child, Adult, Older Adult |
NCT00753831 |
2PR1220827 |
|
January 2009 |
July 2009 |
August 2009 |
September 17, 2008 |
July 12, 2012 |
|
- Aravind Eye Hospital
Madurai, Tamil Nadu, India
|
|
| 45 |
NCT02196155 |
Recruiting |
Botulinum Toxin A Versus Steroids for the Treatment of Chronic Plantar Fasciitis |
|
- Drug: Botulinum toxin A
- Drug: cortisone
- Drug: Saline
|
Interventional
|
Not Applicable |
- University Hospital Inselspital, Berne
- Luzerner Kantonsspital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from baseline in foot pain
- Change from baseline in patient health
- Change from baseline in pain, disability and activity restriction in foot
- (and 4 more...)
|
54 |
All |
18 Years to 60 Years (Adult) |
NCT02196155 |
32003B_152671 |
|
July 2016 |
December 2020 |
June 2021 |
July 21, 2014 |
October 3, 2018 |
|
- Dep, of Orthopaedic Surgery, Inselspital, University of Berne
Berne, Switzerland - Department of Orthopaedic Surgery, Kantonsspital Lucerne
Lucerne, Switzerland
|
|
| 46 |
NCT00210431 |
Completed |
Post Marketing Surveillance Study of Dysport |
- Blepharospasm
- Hemifacial Spasm
- Cervical Dystonia
- (and 6 more...)
|
|
Observational
|
|
|
Industry |
- Observational Model: Other
- Time Perspective: Prospective
|
- - assessment of efficacy as assessed by treating physician at scheduled follow up visit
- - data on adverse events since treatment with Dysport
|
800 |
All |
2 Years and older (Child, Adult, Older Adult) |
NCT00210431 |
Y-47-52120-093 |
|
October 2004 |
|
June 2006 |
September 21, 2005 |
January 25, 2019 |
|
- Centre Hospitalier Saint Esprit
Agen, France - Center Hospitalier du Pays d'Aix
Aix en Provence, France - Centre Hospitalier
Chambery, France - (and 33 more...)
|
|
| 47 |
NCT00773604 |
Completed |
Deep Brain Stimulation in Patients With Dystonia |
|
- Device: Medtronic implantable deep brain stimulation (DBS) system
|
Interventional
|
Phase 1
Phase 2 |
- University of California, San Francisco
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The primary outcome measure is the change in Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) movement score from baseline to 12 months.
|
22 |
All |
7 Years to 80 Years (Child, Adult, Older Adult) |
NCT00773604 |
Private donor |
STN DBS |
June 2008 |
February 2015 |
February 2015 |
October 16, 2008 |
August 7, 2015 |
|
- San Francisco Veterans Administration Medical Center
San Francisco, California, United States - University of California, San Francisco
San Francisco, California, United States
|
|
| 48 |
NCT00082615 |
Completed |
Neurophysiological Markers in Patients With Craniofacial Dystonia and Their Relatives |
|
|
Observational
|
|
- National Institute of Neurological Disorders and Stroke (NINDS)
- National Institutes of Health Clinical Center (CC)
|
NIH |
|
|
210 |
All |
18 Years and older (Adult, Older Adult) |
NCT00082615 |
040188
04-N-0188 |
|
May 11, 2004 |
|
April 21, 2008 |
May 13, 2004 |
July 2, 2017 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
|
| 49 |
NCT02570932 |
Completed |
Administration of Expanded Autologous Adult Bone Marrow Mesenchymal Cells in Established Chronic Spinal Cord Injuries |
|
- Biological: Autologous Mesenchymal Bone Marrow Cell
|
Interventional
|
Phase 2 |
- Puerta de Hierro University Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Changes in IANR-SCIFRS score are considerate for the motor and sensory functions evaluation.
- Neurotrophic factors levels in Cerebrospinal fluid (CSF) and/ or Number of Adverse Events related to treatment
- Changes in PENN score are considerate for the motor and sensory functions evaluation
- (and 3 more...)
|
10 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT02570932 |
CME-LEM3
2014-005613-24 |
|
July 2015 |
December 4, 2017 |
December 4, 2017 |
October 7, 2015 |
April 5, 2018 |
|
- Hospital Puerta de Hierro
Majadahonda, Madrid, Spain
|
|
| 50 |
NCT02291861 |
Completed
Has Results |
Addressing Involuntary Movements in Tardive Dyskinesia |
|
- Drug: SD-809
- Drug: Placebo
|
Interventional
|
Phase 3 |
- Auspex Pharmaceuticals, Inc.
- Teva Pharmaceutical Industries
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Total Motor Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Using a Mixed Model For Repeated Measures (MMRM)
- Percentage of Patients Considered a Treatment Success at Week 12 as Assessed by the Clinical Global Impression of Change (CGIC)
- Change in the Modified Craniocervical Dystonia Questionnaire (mCDQ-24) Total Score From Baseline to Week 12
- (and 5 more...)
|
298 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT02291861 |
SD-809-C-23
2014-003135-19 |
AIM-TD |
October 2014 |
August 2016 |
August 2016 |
November 17, 2014 |
May 14, 2018 |
April 11, 2018 |
- Teva Investigational Site 145
Tuscaloosa, Alabama, United States - Teva Investigational Site 107
Anaheim, California, United States - Teva Investigational Site 108
Anaheim, California, United States - (and 104 more...)
|
|
| 51 |
NCT02195700 |
Completed
Has Results |
Aim to Reduce Movements in Tardive Dyskinesia |
|
- Drug: SD-809
- Drug: Placebo
|
Interventional
|
Phase 2
Phase 3 |
- Auspex Pharmaceuticals, Inc.
- Teva Pharmaceutical Industries
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Centrally Read Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Using Mixed Model Repeated Measures (MMRM) Analysis
- Percentage of Patients Who Are a Treatment Success at Week 12 as Assessed by the Clinical Global Impression of Change (CGIC)
- Percentage of Patients Who Are a Treatment Success at Week 12 as Assessed by the Patient Global Impression of Change (PGIC)
- (and 5 more...)
|
117 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT02195700 |
SD-809-C-18 |
ARM-TD |
June 2014 |
May 2015 |
May 2015 |
July 21, 2014 |
April 17, 2018 |
March 20, 2018 |
- Tuscaloosa, Alabama, United States
- Anaheim, California, United States
- Glendale, California, United States
- (and 38 more...)
|
|
| 52 |
NCT03254186 |
Recruiting |
Safety and Efficacy of Propranolol in the Treatment of Tardive Dyskinesia |
|
- Drug: Propranolol Hydrochloride
- Drug: Placebo Oral Tablet
|
Interventional
|
Phase 2
Phase 3 |
- Emory University
- Atlanta Clinical and Translational Science Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Care Provider, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in the Abnormal Involuntary Movement Scale (AIMS) score.
- Change in the Clinical Global Impression of Severity (CGI-S) score.
- Change in the Clinical Global Impression -Improvement (CGI-I) score.
|
15 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03254186 |
IRB00096912 |
|
September 18, 2017 |
February 1, 2019 |
February 1, 2019 |
August 18, 2017 |
September 28, 2018 |
|
- Emory Clinic, Executive Park
Atlanta, Georgia, United States
|
|
Create an RSS feed from your search for:
Download the search results for: